ADCY9 and coronary artery disorder: This suggests that genetic testing for heart disease risk could have a positive influence on health behaviors like smoking cessation.[17] Jean-Claude Tardif et al in their RCT concluded that dalcetrapib showed potential benefit in reducing cardiovascular morbidity and mortality specifically in patients with the AA genotype at rs1967309 in the ADCY9 gene.[18] The study by Krarup et al investigated the association between a genetic risk score comprising 45 CAD risk variants and the risk of myocardial infarction (MI) in a Danish cohort of 6041 individuals.